Highlights in nanocarriers for the treatment against cervical cancer

Abstract

Cervical cancer is the second most common malignant tumor in women worldwide and has a high mortality rate, especially when it is associated with human papillomavirus (HPV). In US, an estimated 12,820 cases of invasive cervical cancer and an estimated 4210 deaths from this cancer will occur in 2017. With rare and very aggressive conventional treatments, one sees in the real need of new alternatives of therapy as the delivery of chemotherapeutic agents by nanocarriers using nanotechnology. This review covers different drug delivery systems applied in the treatment of cervical cancer, such as solid lipid nanoparticles (SNLs), liposomes, nanoemulsions and polymeric nanoparticles (PNPs). The main advantages of drug delivery thus improving pharmacological activity, improving solubility, bioavailability to bioavailability reducing toxicity in the target tissue by targeting of ligands, thus facilitating new innovative therapeutic technologies in a too much needed area. Among the main disadvantage is the still high cost of production of these nanocarriers. Therefore, the aim this paper is review the nanotechnology based drug delivery systems in the treatment of cervical cancer.

Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy

“…57 The size of NPs provide that they have the capacity of encapsulating drugs. 58 The particle size of NPs synthesized by PBAE ranged from 100 to 400 nm in previous reports. 18,21,59,60 In this study, our NPs were 110.2-174.7 nm in size and were uniformly distributed.…”

Nanomedicine review: clinical developments in liposomal applications

“…It consists of encapsulated doxorubicin hydrochloride, an anticancer drug of the anthracycline family that induces caspase-dependent apoptosis in cancer cells through oxidative DNA Table 3 Evaluation of liposomal bupivacaine (LB) effect on pain scores and narcotic consumption n number of patients, POD postoperative day, VAS visual analogue scale pain score in POD 3 (0-100 range, 0 = "no pain" and 100 = "worst pain"), NRS numerical rating scale pain score in POD 3 (0-10 range, 0 = "no pain" and 10 = "worst pain"), POTO postoperative total opiates consumption a Median consumption of opiates for POD 1-3 damage by blocking topoisomerase IIα, an enzyme needed by cancer cells to divide and grow (Table 5). This enzyme also generates free radicals (reactive oxygen species) that can lead to lipid peroxidation and membrane impairment (Yingchoncharoen et al 2016;Medina-Alarcón et al 2017;Bozzuto and Molinari 2015;Lombardo et al 2016). The composition of different liposomal doxorubicin formulations (Doxil, LipoDox, Myocet, Thermodox, and Caelix), as well as their therapeutic indications and other relevant characteristics are presented in Table 2.…”

“…enhanced solubility and stability of drugs in the organism (Medina-Alarcón et al 2017;Ventola 2017). All these advantages have been reached by using drug delivery systems with 1-100 nm diameter nanoparticles, where a large surface leads to an increase in cellular interactions and multiple alterations of surface properties (Ud Din et al 2017;Senapati et al 2018;Gonda et al 2019).…”

Curcumin-incorporated Thiolated Chitosan/alginate Nanocarriers: Physicochemical Properties and Release Mechanism

“…This could be because curcumin may uniformly disperse in the NPs. Despite the increment, the obtained particle size seems to be optimal according to literatures stating the enhance permeability and retention effect of the tumour may also accumulate the NPs within the tumor [18,19] . The surface charge of the NPs became slightly negative after curcumin was loaded due to the negative charge of curcumin.…”